Abstract
The new and emerging ADC technologies together with the field’s cumulative experience provide new opportunities for ADCs and make them a more promising therapeutic modality than ever before. Despite a rapidly evolving clinical landscape in oncology, there is substantial unmet clinical need that could be addressed by next-generation ADCs. ADCs are also being explored to combat other diseases. This introductory chapter provides context for the key innovations of next-generation ADCs described throughout the volume. A framework for designing and interpreting preclinical pharmacology studies is proposed such that emerging technologies can be rigorously evaluated and molecules can be judiciously optimized.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bialucha CU, Collins SD, Li X, Saxena P, Zhang X, Dürr C, Lafont B, Prieur P, Shim Y, Mosher R, Lee D, Ostrom L, Hu T, Bilic S, Rajlic IL, Capka V, Jiang W, Wagner JP, Elliott G, Veloso A, Piel JC, Flaherty MM, Mansfield KG, Meseck EK, Rubic-Schneider T, London AS, Tschantz WR, Kurz M, Nguyen D, Bourret A, Meyer MJ, Faris JE, Janatpour MJ, Chan VW, Yoder NC, Catcott KC, McShea MA, Sun X, Gao H, Williams J, Hofmann F, Engelman JA, Ettenberg SA, Sellers WR, Lees E (2017) Discovery and optimization of HKT288, a cadherin-6-targeting ADC for the treatment of ovarian and renal cancers. Cancer Discov 7(9):1030–1045. https://doi.org/10.1158/2159-8290.CD-16-1414. Epub 2017 May 19
Chen DS, Mellman I (2017) Elements of cancer immunity and the cancer-immune set point. Nature 541(7637):321–330. https://doi.org/10.1038/nature21349
Damelin M, Bankovich A, Bernstein J, Lucas J, Chen L, Williams S, Park A, Aguilar J, Ernstoff E, Charati M, Dushin R, Aujay M, Lee C, Ramoth H, Milton M, Hampl J, Lazetic S, Pulito V, Rosfjord E, Sun Y, King L, Barletta F, Betts A, Guffroy M, Falahatpisheh H, O’Donnell CJ, Stull R, Pysz M, Escarpe P, Liu D, Foord O, Gerber HP, Sapra P, Dylla SJ (2017) A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions. Sci Transl Med 9(372):pii: eaag2611. https://doi.org/10.1126/scitranslmed.aag2611
Damelin M, Zhong W, Myers J, Sapra P (2015) Evolving strategies for target selection for antibody-drug conjugates. Pharm Res 32(11):3494–3507. https://doi.org/10.1007/s11095-015-1624-3. Epub 2015 Jan 15
Gerber HP, Koehn FE, Abraham RT (2013) The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics. Nat Prod Rep 30(5):625–639. https://doi.org/10.1039/c3np20113a
Lambert JM, Morris CQ (2017) Antibody-drug conjugates (ADCs) for personalized treatment of solid tumors: a review. Adv Ther 34(5):1015–1035. https://doi.org/10.1007/s12325-017-0519-6. Epub 2017 Mar 30
Mosher R, Poling L, Qin L, Bodyak N, Bergstrom D (2017) Relationship of NaPi2b expression and efficacy of XMT-1536, a NaPi2b targeting antibody-drug conjugate (ADC), in an unselected panel of human primary ovarian mouse xenograft models. Presentation at AACR-NCI-EORTC international conference, Philadelphia, 26–30 October 2017
Saunders LR, Bankovich AJ, Anderson WC, Aujay MA, Bheddah S, Black K, Desai R, Escarpe PA, Hampl J, Laysang A, Liu D, Lopez-Molina J, Milton M, Park A, Pysz MA, Shao H, Slingerland B, Torgov M, Williams SA, Foord O, Howard P, Jassem J, Badzio A, Czapiewski P, Harpole DH, Dowlati A, Massion PP, Travis WD, Pietanza MC, Poirier JT, Rudin CM, Stull RA, Dylla SJ (2015) A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med 7(302):302ra136. https://doi.org/10.1126/scitranslmed.aac9459
Sievers EL, Senter PD (2013) Antibody-drug conjugates in cancer therapy. Annu Rev Med 64:15–29
Tolcher AW (2016) Antibody drug conjugates: lessons from 20 years of clinical experience. Ann Oncol 27(12):2168–2172. https://doi.org/10.1093/annonc/mdw424. Epub 2016 Oct 11
Xu Z, Pothula SP, Wilson JS, Apte MV (2014) Pancreatic cancer and its stroma: a conspiracy theory. World J Gastroenterol 20(32):11216–11229. https://doi.org/10.3748/wjg.v20.i32.11216
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Damelin, M. (2018). Introduction: Motivations for Next-Generation ADCs. In: Damelin, M. (eds) Innovations for Next-Generation Antibody-Drug Conjugates. Cancer Drug Discovery and Development. Humana Press, Cham. https://doi.org/10.1007/978-3-319-78154-9_1
Download citation
DOI: https://doi.org/10.1007/978-3-319-78154-9_1
Published:
Publisher Name: Humana Press, Cham
Print ISBN: 978-3-319-78153-2
Online ISBN: 978-3-319-78154-9
eBook Packages: MedicineMedicine (R0)